A congressional panel is pressuring the government agency over its cannabis stance
The lack of regulations on hemp and cannabidiol (CBD) is putting the Food and Drug Administration (FDA) under fire. The new chairman of the GOP congressional panel says he intends to grill the agency and its officials for failing to enact any regulations for hemp-derived products such as CBD on the market.
Representative James Comer was present at a recent interview conducted by the US Hemp Roundtable. During the conversation, Comer said he doesn’t plan to think twice about using his authority as the new chairman of the House Oversight and Accountability Committee to put the head of the FDA under scrutiny. Comer knows that the current regulatory lapse has a long way to go, and CBD regulation should be made a priority.
“I want to bring the FDA commissioner in front of the committee, and this is one of the things that we want to talk about,” Comer, who helped champion federal hemp legalization through the 2018 Farm Bill, said. “It’s not just their lack of action with respect to CBD and other types of hemp-it’s their inaction regarding a lot of areas of their jurisdiction.”
According to the congressman, the agency has the budget and the manpower to be able to move forward with regulating the famous cannabis compound. However, they seem to be doing too much of their work and are way behind schedule.
It is for this reason that Comer wants to bring them to the front of the committee and clarify once and for all what the problem really is. He claims he has been clear enough with the FDA that lawmakers “want hemp to be regulated as a nutraceutical or whatever so that we can have credible hemp companies and where consumers, when they buy hemp, know exactly what is in that hemp and it’s not the wild west out there.”